Mutagenesis Advance Access originally published online on September 28, 2007
Mutagenesis 2007 22(6):409-416; doi:10.1093/mutage/gem036
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
An analysis of results from 305 compounds tested with the yeast RAD54-GFP genotoxicity assay (GreenScreen GC)—including relative predictivity of regulatory tests and rodent carcinogenesis and performance with autofluorescent and coloured compounds
1Gentronix Ltd, CTF Building, 46 Grafton Street, Manchester M13 9NT, UK 2Safety and Environmental Assurance Centre, Unilever, Colworth Park, Sharnbrook, Bedford MK44 1LQ, UK 3Department of Genetic Toxicology, GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP, UK 4Genetics Department, School of Medicine, University of Wales—Swansea, Singleton Park, Swansea SA2 8PP, UK 5Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK 6Centre for Sustainable Water Management, Lancaster Environment Centre, Lancaster LA1 4YQ, UK
Data from 305 non-proprietary compounds tested using the yeast RAD54-GFP (Green Fluorescent Protein) assay, GreenScreen GC, are presented, together with a detailed comparison with results from in vitro and in vivo genotoxicity tests and rodent carcinogenesis. In addition, observations on reproducibility and the performance of the test with autofluorescent and coloured compounds are described. Like the Ames test, the GreenScreen assay is shown to exhibit high specificity (82%), meaning that compounds with positive results are very likely to be genotoxic carcinogens. This is in contrast to mammalian cell tests established for use in regulatory testing that provide disappointingly low specificity and the inevitable generation of confounding false positive data. The analysis confirmed the observations of earlier studies, showing that a combination of an Ames test (or surrogate) with the yeast test provides high specificity as well as high sensitivity in the identification of rodent carcinogens.
* To whom correspondence should be addressed. Tel: +44 (0) 161 606 7266; Fax: +44 (0) 161 606 7337; Email: andrew.knight{at}gentronix.co.uk
Received on June 28, 2007; revised on July 24, 2007; accepted on August 14, 2007.